(Q37750257)

22 August 2017

1 reference

title

A review of the response to oral antidiabetes agents in patients with type 2 diabetes (English)

1 reference

22 August 2017

0 references

James R Gavin

1

1 reference

22 August 2017

Nancy J Bohannon

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

22 August 2017

published in

Postgraduate Medicine

1 reference

22 August 2017

volume

122

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

43-51

1 reference

Standards of medical care in diabetes--2009.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Is glycemic control improving in U.S. adults?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Prognostic factors for successful insulin therapy in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

The PROTECT Study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Indicators for the efficacy of pioglitazone before and during treatment in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Treatment escalation and rise in HbA1c following successful initial metformin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Characteristics of type 2 diabetic patients responding to voglibose administration as an adjunct to sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Hypoglycemia in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for th

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

The nuclear receptor LXR is a glucose sensor

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2141

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.05.2141

1 reference

22 August 2017

1 reference